Fed. Circ. Upholds Most Patents For Allergan Glaucoma Drug
The Federal Circuit ruled Wednesday that only one of the four patents for Allergan Inc.'s glaucoma drug Combigan was invalid, partly reversing a lower court's decision but still preventing Sandoz Inc....To view the full article, register now.
Already a subscriber? Click here to view full article